Led by FTV Capital, with participation from NVIDIA and existing investors, funding will further solidify Kore.ai's leading position in explosive advanced AI market ORLANDO, Fla., Jan. 30, 2024 /PRNewswire/ -- Kore.ai, a leader in enterprise conversational and generative AI platform technology, today announced $150 million in funding. The strategic growth investment was led by FTV Capital, a sector-focused growth equity investor with a successful 25+ year track record investing across enterprise technology, ...

Enfusion, Inc. (NYSE:ENFN) Q3 2023 Results Conference Call November 7, 2023 8:30 AM ET Company Participants Ignatius Njoku - Head, IR Oleg Movchan - CEO Brad Herring - CFO Conference Call Participants Michael Infante - Morgan Stanley Faith Brunner - William Blair Elyse Kanner - JPMorgan Parker Lane - Stifel Crispin Love - Piper Sandler Callie Valenti - Goldman Sachs Natalie Howe - Bank of America Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to Enfusion's Third Quarte ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40949 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 87-1268462 (State or other jurisdictio ...

Enfusion, Inc. (NYSE:ENFN) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Iggy Njoku - Head, IR Oleg Movchan - CEO Brad Herring - CFO Conference Call Participants Kevin McVeigh - Credit Suisse Parker Lane - Stifel James Faucette - Morgan Stanley Callie Valenti - Goldman Sachs Dylan Becker - William Blair Operator Good morning, ladies and gentlemen, and thank you for standing by. Welcome to Enfusion Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a rem ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40949 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 87-1268462 (State or other jurisdiction of ...

Enfusion, Inc. (NYSE:ENFN) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Ignatius Njoku - Head, IR Oleg Movchan - CEO Brad Herring - CFO Conference Call Participants Dylan Becker - William Blair James Faucette - Morgan Stanley J. Parker Lane - Stifel Nicolaus Koji Ikeda - Bank of America Operator Good morning, ladies and gentlemen. Thank you for standing by. Welcome to Enfusion's First Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conferenc ...

¨·· ënfusion PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. ©2023 ENFUSION. ALL RIGHTS RESERVED. 2 Statements we make in this presentation may include statements which are not historical facts and are considered forwardlooking within the meaning of Section 27A of the Securities Act of 1933 (Securities Act) and Section 21E of the Securities Exchange Act of 1934 (Exchange Act), including expectations regarding future financial performance. These forward-looking statements are usually identi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40949 Enfusion, Inc. (Exact name of registrant as specified in its charter) Delaware 87-1268462 (State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-40949 ENFUSION, INC. (Exact name of registrant as specified in its charter) Delaware 87-1268462 (State of Other Jurisdiction of incorporation o ...

Enfusion, Inc. (NYSE:ENFN) Q4 2022 Results Conference Call March 7, 2023 8:30 AM ET Company Participants Ignatius Njoku - Head, IR Oleg Movchan - CEO Brad Herring - CFO Conference Call Participants James Faucette - Morgan Stanley Kevin McVeigh - Credit Suisse Dylan Becker - William Blair Koji Ikeda - Bank of America Matthew Kikkert - Stifel Operator Good morning, ladies and gentlemen and thank you for standing by. Welcome to Enfusion's Fourth Quarter 2022 Earnings Conference Call. [Operator Instructions] A ...